Extended Outpatient Gynecologic Surgery PostOp [1442]

General

| Common Present on Admission Diagnosis | |
|---|--|
| [] Acidosis | Post-op |
| [] Acute Post-Hemorrhagic Anemia | Post-op |
| [] Acute Renal Failure | Post-op |
| [] Acute Respiratory Failure | Post-op |
| [] Acute Thromboembolism of Deep Veins of Lower | Post-op |
| Extremities | |
| [] Anemia | Post-op |
| [] Bacteremia | Post-op |
| [] Bipolar disorder, unspecified | Post-op |
| [] Cardiac Arrest | Post-op |
| [] Cardiac Dysrhythmia | Post-op |
| [] Cardiogenic Shock | Post-op |
| [] Decubitus Ulcer | Post-op |
| Dementia in Conditions Classified Elsewhere | Post-op |
| [] Disorder of Liver | Post-op |
| [] Electrolyte and Fluid Disorder | Post-op |
| [] Intestinal Infection due to Clostridium Difficile | Post-op |
| [] Methicillin Resistant Staphylococcus Aureus Infection | Post-op |
| [] Obstructive Chronic Bronchitis with Exacerbation | Post-op |
| [] Other Alteration of Consciousness | Post-op |
| [] Other and Unspecified Coagulation Defects | Post-op |
| [] Other Pulmonary Embolism and Infarction | Post-op |
| Phlebitis and Thrombophlebitis | Post-op |
| Protein-calorie Malnutrition | Post-op |
| [] Psychosis, unspecified psychosis type | Post-op |
| [] Schizophrenia Disorder | Post-op |
| [] Sepsis | Post-op |
| [] Septic Shock | Post-op |
| [] Septicemia | Post-op |
| [] Type II or Unspecified Type Diabetes Mellitus with Mention of Complication, Not Stated as Uncontrolled | Post-op |
| [] Urinary Tract Infection, Site Not Specified | Post-op |
| | |
| Elective Outpatient, Observation, or Admission (Single | Response) |
| () Elective outpatient procedure: Discharge following routine recovery | Routine, Continuous, PACU & Post-op |
| () Outpatient observation services under general | Diagnosis: |
| supervision | Admitting Physician: |
| | Patient Condition: |
| | Bed request comments: |
| | PACU & Post-op |
| () Outpatient in a bed - extended recovery | Diagnosis: |
| | Admitting Physician: |
| | Bed request comments: |
| | PACU & Post-op |
| () Admit to Inpatient | Diagnosis: |
| | Admitting Physician: |
| | Level of Care: |
| | Patient Condition: |
| | Bed request comments: |
| | Certification: I certify that based on my best clinical judgment |
| | and the patient's condition as documented in the HP and |
| | progress notes, I expect that the patient will need hospital |
| | services for two or more midnights. |
| | PACU & Post-op |
| Printed on 9/17/2020 at 8:36 AM from SUP | Page 1 of 19 |

| Admission | or Observat | ion (Single | Response) |
|------------|----------------|----------------|-----------------|
| Patient ha | as active outp | oatient status | s order on file |

| () Admit to Inpatient | Diagnosis: Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. |
|---|--|
| () Outpatient observation services under general supervision | PACU & Post-op Diagnosis: Admitting Physician: Patient Condition: Bed request comments: |
| () Outpatient in a bed - extended recovery | PACU & Post-op Diagnosis: Admitting Physician: Bed request comments: PACU & Post-op |
| () Transfer patient | Level of Care: Bed request comments: Scheduling/ADT |
| () Return to previous bed Admission (Single Response) Patient has active status order on file | Routine, Until discontinued, Starting S, Scheduling/ADT |
| () Admit to inpatient | Diagnosis: Admitting Physician: Level of Care: Patient Condition: Bed request comments: Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights. PACU & Post-op |
| () Transfer patient | Level of Care: Bed request comments: Scheduling/ADT |
| Return to previous bed Transfer (Single Response) Patient has active inpatient status order on file | Routine, Until discontinued, Starting S, Scheduling/ADT |
| () Transfer patient | Level of Care: Bed request comments: Scheduling/ADT |
| () Return to previous bed | Routine, Until discontinued, Starting S, Scheduling/ADT |
| Code Status [] Full Code | Code Status decision reached by: Post-op |
| DNR (Do Not Resuscitate) (Selection Required) Do D | oes patient have decision-making capacity? |

| [] Consult to Palliative Care Service | Priority: Reason for Consult? Order? Name of referring provider: Enter call back number: |
|--|--|
| [] Consult to Social Work | Reason for Consult: Post-op |
| [] Modified Code | Does patient have decision-making capacity? Modified Code restrictions: Post-op |
| [] Treatment Restrictions | Treatment Restriction decision reached by: Specify Treatment Restrictions: Post-op |
| Isolation | |
| [] Airborne isolation status | |
| [] Airborne isolation status | Details |
| Mycobacterium tuberculosis by PCR - If you suspect Tuberculosis, please order this test for rapid diagnostics. | Once, Sputum, Post-op |
| [] Contact isolation status | Details |
| Droplet isolation status | Details |
| [] Enteric isolation status | Details |
| Precautions | |
| Aspiration precautions | Post-op |
| [] Fall precautions | Increased observation level needed: Post-op |
| [] Latex precautions | Post-op |
| [] Seizure precautions | Increased observation level needed: Post-op |
| Nursing | |
| Vital Signs | |
| [X] Vital signs - T/P/R/BP | Routine, Per unit protocol, Post-op |
| Activity | |
| [] Dangle at bedside | Routine, Once |
| [V] Un in chair | After 6 hours postop |
| [X] Up in chair | Routine, Until discontinued, Starting S Specify: Up in chair |
| | Additional modifier: |
| | This evening , Post-op |
| [X] Ambulate with assistance | Routine, Now then every 4 hours |
| | Specify: with assistance |
| | Post-op |
| Nursing Postoperative Day | |
| [] Saline lock IV | Routine, Continuous, Post-op |
| [X] Encourage deep breathing and coughing | Routine, Every 2 hours while awake Until ambulatory, Post-op |
| [X] Incentive spirometry | Routine, Every 2 hours while awake Place at bedside. Encourage patient to use., Post-op |
| [] Initiate discharge planning | Routine, Once, Post-op |
| Nursing POD 1 | |
| [X] Foley catheter - discontinue | Routine, Once, Starting S+1 at 6:00 AM, Post-op |

| [] Patient education-review discharge plan | Routine, Once, Starting S+1 |
|--|--|
| | Patient/Family: |
| | Education for: Discharge |
| | Review discharge plan. Instruct patient to continue over the |
| [1] Debie west | counter stool softener/laxative as needed., Post-op |
| [] Pelvic rest | Routine, Once For 1 Occurrences Pelvic rest for: |
| | Post-op |
| [] Remove abdominal dressing | Routine, Once, Starting S+1 |
| [] Remove abdominal dressing | Dressing location : |
| | Remove abdominal dressing, Post-op |
| Remove vaginal packing | Routine, Once, Starting S+1 |
| [1] common confirm promise | Dressing location : |
| | Remove vaginal packing, Post-op |
| Nursing wound care | Routine, Daily, Starting S+1 |
| | Location: |
| | Site: |
| | Irrigate wound? |
| | Apply: |
| | Dressing Type: |
| [1] Coling leads IV | Clean incision with water, Post-op |
| [] Saline lock IV | Routine, Continuous, Starting S+1, Post-op |
| [] Discontinue IV | Routine, Once, Starting S+1 On POD 1 if patient is afebrile and tolerating diet, Post-op |
| [] Discontinue PCA/Epidural | Routine, Until discontinued, Starting S+1 |
| [] Discontinue PCA/Epidural | Prior to discontinuing foley, Post-op |
| Discontinue PCA basal rate | Routine, Until discontinued, Starting S+1, Post-op |
| [] Wean epidural basal rate | Routine, Until discontinued, Starting S+1, Post-op |
| Dost-op voiding trial | Routine, Once, Starting S+1, Post-op |
| [] 1 Ost-op volding than | Routine, Onde, Starting O. 1, 1 Ost-op |
| Diet | |
| [1] NDO expert ice chine | Diet offective new Starting S |
| [] NPO except ice chips | Diet effective now, Starting S NPO: Except Ice chips |
| | Pre-Operative fasting options: |
| | Until no longer nauseated, Post-op |
| Diet Advance as tolerated | Diet effective now, Starting S |
| | Diet(s): |
| | Advance Diet as Tolerated? Yes |
| | Target Diet: Regular |
| | Advance target diet criteria: NPO except ice chips until no |
| | nausea. Clear liquids until patient has passed flatus and then |
| | advance to Soft, Easy to Digest. |
| | Liquid Consistency: |
| | Fluid Restriction: Foods to Avoid: |
| | Post-op |
| [] Diet - Regular | Diet effective now, Starting S |
| [] Dist Regular | Diet(s): Regular |
| | Advance Diet as Tolerated? |
| | Liquid Consistency: |
| | Fluid Restriction: |
| | Foods to Avoid: |
| | Post-op |
| D/EL: | |
| IV Fluids | |
| IV Fluids | |
| | 40E mal /hm imbrassertimes Dect. |
| [X] lactated Ringer's infusion | 125 mL/hr, intravenous, continuous, Post-op |
| [] dextrose 5 % and lactated Ringer's infusion | 125 mL/hr, intravenous, continuous, Post-op |
| Madications | |
| Medications | |
| | |

|) cefazolin (ANCEF) IV | | 2 g, intravenous, once, For 1 Doses, Post-op Reason for Therapy: |
|---|-------------------|--|
| Antibiotics: cefazolin (ANCEF) for patients GREA | TER than | 120 kg (Single Response) |
|) cefazolin (ANCEF) IV | | 3 g, intravenous, once, For 1 Doses, Post-op Reason for Therapy: |
| Antibiotics: if Penicillin or Beta-Lactam Allergic | ose ONE | option from Section 1 and ONE option from Section 2. |
| ii patient is remoillin of beta-Lactain Allergic. One | OSC ONL | option nonrection 1 and one option nonrection 2. |
|] Section 1 (Single Response) | | |
| () metronidazole (FLAGYL) IV | For pen | , intravenous, once, For 1 Doses, Post-op icillin or beta-lactam allergic patients. for Therapy: |
| clindamycin (CLEOCIN) IV - Recommended ONLY for patients with high risk for penicillin anaphylaxis that are culture isolate sensitive to Clindamycin. | 900 mg For pen | , intravenous, for 30 Minutes, once, For 1 Doses, Post-op icillin or beta-lactam allergic patients. for Therapy: |
|] Section 2 (Single Response) | | |
| () levofloxacin (LEVAQUIN) IV | For pen | , intravenous, once, For 1 Doses, Post-op icillin or beta-lactam allergic patients. for Therapy: |
| () gentamicin (GARAMYCIN) IV | 80 mg, For pen | intravenous, for 30 Minutes, once, For 1 Doses, Post-op icillin or beta-lactam allergic patients. for Therapy: |
| fild Pain (Pain Score 1-3) (Single Response) | | |
|) acetaminophen (TYLENOL) tablet | - | 650 mg, oral, every 6 hours PRN, mild pain (score 1-3), Post-op |
| ibuprofen (ADVIL,MOTRIN) tablet - Not recomme in patients with eGFR LESS than 30 mL/min OR kidney injury | | 600 mg, oral, every 6 hours PRN, mild pain (score 1-3), Post-op |
|) traMADol (ULTRAM) tablet - Not recommended patients with eGFR LESS than 30 mL/min OR in kidney injury | | 25 mg, oral, every 6 hours PRN, mild pain (score 1-3), Post-op Not recommended in patients with eGFR LESS than 30 mL/min OR in acutekidney injury. Not to exceed 400 mg/day |
| Moderate Pain (Pain Score 4-6) (Single Response |)) | |
|) acetaminophen-codeine (TYLENOL #3) 300-30 r tablet | <u> </u> | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6). Post-op |
|) HYDROcodone-acetaminophen (NORCO) 5-325 tablet | mg per | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6) Post-op |
|) oxyCODONE-acetaminophen (PERCOCET) 5-3: per tablet | 25 mg | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6) Post-op |
| ketorolac (TORADOL) tablet - Not recommended patients with eGFR LESS than 30 mL/min OR in kidney injury | | 10 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op Not recommended in patients with eGFR LESS than 30 |
| | - | mL/min OR in acutekidney injury |
|) ketorolac (TORADOL) IV (Single Response) Do NOT use in patients with eGFR LESS than 30 WARNING: Use is contraindicated for treatment (CABG) surgery. | | AND/OR patients LESS than 17 years of age. rative pain OR in the setting of coronary artery bypass graft |
| () For patients ages GREATER than 64 OR weight LESS than 50 kg OR eGFR 30-59 mL/min - ketorolac (TORADOL) injection | 15 mg, | intravenous, every 6 hours PRN, moderate pain (score 4-6) |
| () For patients ages 17-64 AND weight GREATER than or EQUAL to 50 kg AND eGFR at least 60 mL/min - ketorolac | 30 mg, | intravenous, every 6 hours PRN, moderate pain (score 4-6) |
| (TORADOL) injection inted on 9/17/2020 at 8:36 AM from SUP | | Page 5 of |

| Severe Pain (Pain Score 7-10) (Single Response) | |
|---|---|
|) morPHINE injection | 4 mg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op And Notify MD. |
|) HYDROmorphone (DILAUDID) injection | 0.8 mg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op |
| Antiemetics - HMH, HMSJ, HMW, HMSTC Only | |
| X] ondansetron (ZOFRAN) IV or Oral (Selection Re | quired) "Or" Linked Panel |
| [X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet | 4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is able to tolerate oral medication. |
| [X] ondansetron (ZOFRAN) 4 mg/2 mL injection | 4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is UNable to tolerate oral medication OR if a faster onset action is required. |
| X] promethazine (PHENERGAN) IV or Oral or Rect | al "Or" Linked Panel |
| [X] promethazine (PHENERGAN) 12.5 mg IV | 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required |
| [X] promethazine (PHENERGAN) tablet | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolera oral medication. |
| [X] promethazine (PHENERGAN) suppository | 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. |
| Antiemetics - HMSL, HMWB Only | |
| X] ondansetron (ZOFRAN) IV or Oral (Selection Re | quired) "Or" Linked Panel |
| [X] ondansetron ODT (ZOFRAN-ODT) | 4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op |
| disintegrating tablet [X] ondansetron (ZOFRAN) 4 mg/2 mL injection | Give if patient is able to tolerate oral medication. 4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op |
| [A] Glidansetion (2011AN) 4 mg/2 mc injection | Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required. |
| X] promethazine (PHENERGAN) IV or Oral or Rect | · |
| [X] promethazine (PHENERGAN) 12.5 mg in | 12.5 mg, intravenous, at 60 mL/hr, for 20 Minutes, every 6 hours PRN, |
| sodium chloride 0.9 % 0.9 % 20 mL for Alaris pump syringe option | nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is require |
| [X] promethazine (PHENERGAN) tablet | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op |
| [] promounation (| Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolera oral medication. |
| [X] promethazine (PHENERGAN) suppository | 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication. |
| Antiemetics - HMSTJ Only | |
| X] ondansetron (ZOFRAN) IV or Oral (Selection Re | |
| [X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet | 4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is able to tolerate oral medication. |
| [X] ondansetron (ZOFRAN) 4 mg/2 mL injection | 4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is UNable to tolerate oral medication OR if a faster onset action is required. |
| K] promethazine (PHENERGAN) IVPB or Oral or R | |
| [X] promethazine (PHENERGAN) 25 mg in sodium chloride 0.9 % 50 mL IVPB | 12.5 mg, intravenous, for 30 Minutes, every 6 hours PRN, nausea, vomiting, Post-op |
| IVI promothoging (DLIENEDCANI) to block | Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. |
| [X] promethazine (PHENERGAN) tablet | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolera oral medication. |

oral medication.

| stipation sides-docusate sodium (SENOKOT-S) 8.6-50 blet esium hydroxide suspension - NOT MMENDED FOR CHRONIC KIDNEY DISEA E 3 OR WORSE bdyl (DULCOLAX) EC tablet bdyl (DULCOLAX) suppository nicone (MYLICON) chewable tablet teners ate sodium (COLACE) capsule or Patients LESS than 70 years old (Single hydrAMINE (BENADRYL) tablet nadine (ALLEGRA) tablet - For eGFR LESS t /min, reduce frequency to once daily as need teon (ROZEREM) tablet | 30 mL, oral, every 12 hours PRN, constipation, Post-op Do not give if patient is on hemodialysis or is in chronic renal failure. 10 mg, oral, daily PRN, constipation, Post-op 10 mg, rectal, daily PRN, constipation, Post-op 160 mg, oral, 4 times daily PRN, flatulence, Post-op 100 mg, oral, 2 times daily, Post-op Response) 25 mg, oral, every 6 hours PRN, itching, Post-op han 60 mg, oral, 2 times daily PRN, itching, Post-op ed |
|---|---|
| polet desium hydroxide suspension - NOT MMENDED FOR CHRONIC KIDNEY DISEA E 3 OR WORSE ddyl (DULCOLAX) EC tablet ddyl (DULCOLAX) suppository nicone (MYLICON) chewable tablet teners ate sodium (COLACE) capsule or Patients LESS than 70 years old (Single hydramine (ALLEGRA) tablet - For eGFR LESS to finin, reduce frequency to once daily as need : For Patients GREATER than or EQUAL to | 30 mL, oral, every 12 hours PRN, constipation, Post-op Do not give if patient is on hemodialysis or is in chronic renal failure. 10 mg, oral, daily PRN, constipation, Post-op 10 mg, rectal, daily PRN, constipation, Post-op 160 mg, oral, 4 times daily PRN, flatulence, Post-op 100 mg, oral, 2 times daily, Post-op Response) 25 mg, oral, every 6 hours PRN, itching, Post-op han 60 mg, oral, 2 times daily PRN, itching, Post-op ed |
| MMENDED FOR CHRONIC KIDNEY DISEA E 3 OR WORSE odyl (DULCOLAX) EC tablet odyl (DULCOLAX) suppository nicone (MYLICON) chewable tablet teners ate sodium (COLACE) capsule or Patients LESS than 70 years old (Single hydrAMINE (BENADRYL) tablet nadine (ALLEGRA) tablet - For eGFR LESS t/min, reduce frequency to once daily as need : For Patients GREATER than or EQUAL to | Do not give if patient is on hemodialysis or is in chronic renal failure. 10 mg, oral, daily PRN, constipation, Post-op 10 mg, rectal, daily PRN, constipation, Post-op 160 mg, oral, 4 times daily PRN, flatulence, Post-op 100 mg, oral, 2 times daily, Post-op 25 mg, oral, every 6 hours PRN, itching, Post-op han 60 mg, oral, 2 times daily PRN, itching, Post-op ed |
| dyl (DULCOLAX) suppository nicone (MYLICON) chewable tablet teners ate sodium (COLACE) capsule or Patients LESS than 70 years old (Single hydrAMINE (BENADRYL) tablet nadine (ALLEGRA) tablet - For eGFR LESS thin, reduce frequency to once daily as need: For Patients GREATER than or EQUAL to | 10 mg, rectal, daily PRN, constipation, Post-op 160 mg, oral, 4 times daily PRN, flatulence, Post-op 100 mg, oral, 2 times daily, Post-op Response) 25 mg, oral, every 6 hours PRN, itching, Post-op han 60 mg, oral, 2 times daily PRN, itching, Post-op ed |
| nicone (MYLICON) chewable tablet teners ate sodium (COLACE) capsule or Patients LESS than 70 years old (Single hydrAMINE (BENADRYL) tablet nadine (ALLEGRA) tablet - For eGFR LESS t /min, reduce frequency to once daily as need | 160 mg, oral, 4 times daily PRN, flatulence, Post-op 100 mg, oral, 2 times daily, Post-op Response) 25 mg, oral, every 6 hours PRN, itching, Post-op han 60 mg, oral, 2 times daily PRN, itching, Post-op ed |
| teners ate sodium (COLACE) capsule or Patients LESS than 70 years old (Single hydrAMINE (BENADRYL) tablet nadine (ALLEGRA) tablet - For eGFR LESS t /min, reduce frequency to once daily as need | 100 mg, oral, 2 times daily, Post-op Response) 25 mg, oral, every 6 hours PRN, itching, Post-op han 60 mg, oral, 2 times daily PRN, itching, Post-op ed |
| teners ate sodium (COLACE) capsule or Patients LESS than 70 years old (Single hydrAMINE (BENADRYL) tablet nadine (ALLEGRA) tablet - For eGFR LESS t /min, reduce frequency to once daily as need | 100 mg, oral, 2 times daily, Post-op Response) 25 mg, oral, every 6 hours PRN, itching, Post-op han 60 mg, oral, 2 times daily PRN, itching, Post-op ed |
| ate sodium (COLACE) capsule or Patients LESS than 70 years old (Single hydrAMINE (BENADRYL) tablet nadine (ALLEGRA) tablet - For eGFR LESS t /min, reduce frequency to once daily as need : For Patients GREATER than or EQUAL to | 25 mg, oral, every 6 hours PRN, itching, Post-op han 60 mg, oral, 2 times daily PRN, itching, Post-op ed |
| nhydrAMINE (BENADRYL) tablet nadine (ALLEGRA) tablet - For eGFR LESS t /min, reduce frequency to once daily as need : For Patients GREATER than or EQUAL to | 25 mg, oral, every 6 hours PRN, itching, Post-op han 60 mg, oral, 2 times daily PRN, itching, Post-op ed |
| nhydrAMINE (BENADRYL) tablet nadine (ALLEGRA) tablet - For eGFR LESS t /min, reduce frequency to once daily as need : For Patients GREATER than or EQUAL to | 25 mg, oral, every 6 hours PRN, itching, Post-op han 60 mg, oral, 2 times daily PRN, itching, Post-op ed |
| nadine (ALLEGRA) tablet - For eGFR LESS t /min, reduce frequency to once daily as need : For Patients GREATER than or EQUAL to | han 60 mg, oral, 2 times daily PRN, itching, Post-op ed |
| | |
| eon (ROZEREM) tablet | 70 years old (Single Response) |
| CON (NOZENENI) tablet | 8 mg, oral, nightly PRN, sleep, Post-op |
| : For Patients LESS than 70 years old (Sing | gle Response) |
| | 5 mg, oral, nightly PRN, sleep, Post-op |
| | 8 mg, oral, nightly PRN, sleep, Post-op |
| | |
| | |
| and Prophylaxis Tool (Single Response) (| Selection Required) URL: "\appt1.pdf" |
| | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op |
| Risk of DVT (Selection Required) | · |
| | ors |
| Risk (Single Response) (Selection Required |) |
| | Routine, Once |
| | Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourge early ambulation PACU & Post-op |
| t | em (AMBIEN) tablet teon (ROZEREM) tablet and Prophylaxis Tool (Single Response) (and currently has an active order for therapeutic agulant or VTE prophylaxis Risk of DVT (Selection Required) Risk Definition ess than 60 years and NO other VTE risk factor V Risk (Single Response) (Selection Required ow risk of VTE |

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

| Moderate Risk (Selection Required) Moderate risk of VTE | Routine, Once, PACU & Post-op |
|---|---|
| Moderate Risk Pharmacological Prophylaxis - | |
| Patient (Single Response) (Selection Required | |
| () Contraindications exist for pharmacologic pro BUT order Sequential compression device | ophylaxis "And" Linked Panel |
| [] Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| [] Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |
| () Contraindications exist for pharmacologic pro | pphylaxis "And" Linked Panel |
| [] Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| [] Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| () enoxaparin (LOVENOX) injection (Single Res (Selection Required) | sponse) |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 0600, Starting S+1 |
| () patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min |
| () patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| () patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 3 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| | D 0 1 |

| () warfarin (COUMADIN) tablet | oral, daily at 1700, Starting S+1, PACU & Post-op Indication: | |
|--|---|--|
| () Pharmacy consult to manage warfarin | STAT, Until discontinued, Starting S | |
| (COUMADIN) | Indication: | |
| () MODERATE Risk of DVT - Non-Surgical (Selection | | |

 MODERATE Risk of DVT - Non-Surgical (Selection Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

| Routine, Once, PACU & Post-op |
|--|
| tion |
| phylaxis - "And" Linked Panel |
| Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| Routine, Continuous, PACU & Post-op |
| ohylaxis "And" Linked Panel |
| Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| ponse) |
| 40 mg, subcutaneous, daily at 1700, Starting S |
| 30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min |
| 30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| 40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| 2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| |

| () | heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, PACU & Post-op |
|-----------------|---|---|
| () | heparin (porcine) injection (Recommended | 5,000 Units, subcutaneous, every 12 hours, PACU & Post-op |
| | for patients with high risk of bleeding, e.g. | Recommended for patients with high risk of bleeding, e.g. weight LESS |
| | weight < 50kg and age > 75yrs) | than 50kg and age GREATER than 75yrs. |
| () | warfarin (COUMADIN) tablet | oral, daily at 1700, PACU & Post-op |
| | , | Indication: |
| $\overline{()}$ | Pharmacy consult to manage warfarin | STAT, Until discontinued, Starting S |
| , | (COUMADIN) | Indication: |

() HIGH Risk of DVT - Surgical (Selection Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

|] High Risk (Selection Required) | |
|--|---|
| [] High risk of VTE | Routine, Once, PACU & Post-op |
| High Risk Pharmacological Prophylaxis - Surgi (Single Response) (Selection Required) | cal Patient |
| () Contraindications exist for pharmacologic | Routine, Once |
| prophylaxis | No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| | PACU & Post-op |
| () enoxaparin (LOVENOX) injection (Single Res (Selection Required) | |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 0600, Starting S+1 |
| () patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min |
| () patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 |
| CICI GREATER (Hall 50 HE/HIII) | mL/min |
| () patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op |
| () heparin (porcine) injection (Recommended | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & |
| for patients with high risk of bleeding, e.g. | Post-op |
| weight < 50kg and age > 75yrs) | Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700, Starting S+1, PACU & Post-op Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |

^[] Mechanical Prophylaxis (Single Response) (Selection Required)

| | () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
|-----|---|--|
| | () Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |
| / \ | 1110115:1 (D)(T N 0 : 1/0 1 :: 5 | . 1) |

() HIGH Risk of DVT - Non-Surgical (Selection Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

| [] High risk of VTE | Routine, Once, PACU & Post-op |
|---|---|
| High Risk Pharmacological Prophylaxis - Non-Su Patient (Single Response) (Selection Required) | irgical |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| () enoxaparin (LOVENOX) injection (Single Responsable (Selection Required) | |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 1700, Starting S |
| () patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min |
| () patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| () patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 3 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| Mechanical Prophylaxis (Single Response) (Sele Required) | ction |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s PACU & Post-op |
| () Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |

Required)

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

| [] High Risk (Selection Required) [] High risk of VTE [] High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response) (Selection Required) () Contraindications exist for pharmacologic prophylaxis () apixaban (ELIQUIS) tablet () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe () enoxaparin | |
|---|----------|
| High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response) (Selection Required) Contraindications exist for pharmacologic prophylaxis | |
| (Arthroplasty) Surgical Patient (Single Response) (Selection Required) () Contraindications exist for pharmacologic prophylaxis | |
| () Contraindications exist for pharmacologic prophylaxis () apixaban (ELIQUIS) tablet () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For | |
| prophylaxis No pharmacologic VTE prophylaxis due to the following contraindication(s): () apixaban (ELIQUIS) tablet 2.5 mg, oral, every 12 hours, Starting S+1 Indications: () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min. () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL) | |
| contraindication(s): () apixaban (ELIQUIS) tablet 2.5 mg, oral, every 12 hours, Starting S+1 Indications: () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min. () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI | |
| () apixaban (ELIQUIS) tablet 2.5 mg, oral, every 12 hours, Starting S+1 Indications: () aspirin chewable tablet () aspirin (ECOTRIN) enteric coated tablet () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min. () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI | |
| Indications: () aspirin chewable tablet | |
| () aspirin (ECOTRIN) enteric coated tablet 162 mg, oral, daily, Starting S+1 () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI | |
| () enoxaparin (LOVENOX) injection (Single Response) (Selection Required) () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) | |
| () enoxaparin (LOVENOX) syringe 40 mg, subcutaneous, daily at 0600, Starting S+1 () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI | |
| () enoxaparin (LOVENOX) syringe 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min. 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI Starting S+1) | |
| Starting S+1 () enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min. () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI | |
| Patients with CrCL LESS than 30 mL/min () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI | CAL), |
| () enoxaparin (LOVENOX) syringe - For 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI | |
| | |
| Patients weight between 100-139 kg and Starting S+1 | CAL), |
| | |
| CrCl GREATER than 30 mL/min For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min. | |
| () enoxaparin (LOVENOX) syringe - For 40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITI | CAL), |
| Patients weight between 140 kg or Starting S+1 | |
| GREATER and CrCl GREATER than 30 For Patients weight 140 kg or GREATER and CrCl GREATER to | han 30 |
| mL/min mL/min | |
| () fondaparinux (ARIXTRA) injection 2.5 mg, subcutaneous, daily, Starting S+1 | |
| If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this me | dication |
| Contraindicated in patients LESS than 50kg, prior to surgery/inva | |
| procedure, or CrCl LESS than 30 mL/min | SIVC |
| This patient has a history of or suspected case of Heparin-Induce | ed |
| Thrombocytopenia (HIT): | |
| () heparin (porcine) injection 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM | |
| () heparin (porcine) injection (Recommended 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM | |
| for patients with high risk of bleeding, e.g. Recommended for patients with high risk of bleeding, e.g. weight | LESS |
| weight < 50kg and age > 75yrs) than 50kg and age GREATER than 75yrs. | |
| () rivaroxaban (XARELTO) tablet for hip or 10 mg, oral, daily at 0600 (TIME CRITICAL), Starting S+1 | |
| knee arthroplasty planned during this To be Given on Post Op Day 1. | |
| admission Indications: | |
| () warfarin (COUMADIN) tablet oral, daily at 1700, Starting S+1 Indication: | |
| () Pharmacy consult to manage warfarin STAT, Until discontinued, Starting S Indication: | |

Required)

Mechanical Prophylaxis (Single Response) (Selection

| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
|---|---|
| () Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |
| DVT Risk and Prophylaxis Tool (Single Response) | URL: "\appt1.pdf" |
| () Patient currently has an active order for therapeutic anticoagulant or VTE prophylaxis | Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op |
| () LOW Risk of DVT (Selection Required) | · |
| Low Risk Definition Age less than 60 years and NO other VTE risk factors | ors |
| [] Low Risk (Single Response) (Selection Required | |
| () Low risk of VTE | Routine, Once Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae early ambulation PACU & Post-op |
| () MODERATE Risk of DVT - Surgical (Selection Req | uired) |
| contraindicated. One or more of the following medical conditions: CHF, MI, lung disease, pneumonia, active inflamma stroke, rheumatologic disease, sickle cell disease, I Age 60 and above Central line History of DVT or family history of VTE Anticipated length of stay GREATER than 48 hours Less than fully and independently ambulatory Estrogen therapy Moderate or major surgery (not for cancer) Major surgery within 3 months of admission | ation, dehydration, varicose veins, cancer, sepsis, obesity, previous eg swelling, ulcers, venous stasis and nephrotic syndrome |
| [] Moderate Risk (Selection Required) [] Moderate risk of VTE | Routine, Once, PACU & Post-op |
| [] Moderate Risk Pharmacological Prophylaxis - Su | |
| Patient (Single Response) (Selection Required) () Contraindications exist for pharmacologic prophers of the properties | nylaxis "And" Linked Panel |
| BUT order Sequential compression device [] Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| [] Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |
| Contraindications exist for pharmacologic proph AND mechanical prophylaxis | nylaxis "And" Linked Panel |
| [] Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| [] Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |

| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 0600, Starting S+1 |
|---|--|
| () patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min |
| () patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| () patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700, Starting S+1, PACU & Post-op Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |

Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

|] Moderate risk of VTE | Routine, Once, PACU & Post-op |
|---|---|
| Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) (Select Required) | tion |
| Contraindications exist for pharmacologic prop Order Sequential compression device | ohylaxis - "And" Linked Panel |
| [] Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |

AND mechanical prophylaxis

| | Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
|--------|---|--|
| | Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| | noxaparin (LOVENOX) injection (Single Respo Selection Required) | onse) |
| () e | enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 1700, Starting S |
| () p | patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min |
| | patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
| | patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () for | ndaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () he | eparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, PACU & Post-op |
| for | eparin (porcine) injection (Recommended r patients with high risk of bleeding, e.g. eight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () wa | arfarin (COUMADIN) tablet | oral, daily at 1700, PACU & Post-op Indication: |
| | narmacy consult to manage warfarin COUMADIN) | STAT, Until discontinued, Starting S Indication: |
|) HIGH | Risk of DVT - Surgical (Selection Required) | |
| | | |

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

| [] High risk of VTE | Routine, Once, PACU & Post-op |
|--|---|
| [] High Risk Pharmacological Prophylaxis - Surg (Single Response) (Selection Required) | ical Patient |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| () enoxaparin (LOVENOX) injection (Single Res (Selection Required) | sponse) |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 0600, Starting S+1 |
| () patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 0600, Starting S+1 For Patients with CrCL LESS than 30 mL/min |

| () patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |
|---|---|
| () patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700, Starting S+1, PACU & Post-op Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| [] Mechanical Prophylaxis (Single Response) (Sel Required) | ection |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| () Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |
| HIGH Risk of DVT - Non-Surgical (Selection Requ | ired) |
| | |

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

| [] High Risk (Selection Required) | |
|---|---|
| [] High risk of VTE | Routine, Once, PACU & Post-op |
| [] High Risk Pharmacological Prophylaxis - Non-Spatient (Single Response) (Selection Required | |
| () Contraindications exist for pharmacologic prophylaxis | Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| () enoxaparin (LOVENOX) injection (Single Res (Selection Required) | ponse) |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 1700, Starting S |
| () patients with CrCL LESS than 30 mL/min | 30 mg, subcutaneous, daily at 1700, Starting S For Patients with CrCL LESS than 30 mL/min |
| () patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily, Starting S For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min |

| () patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily, Starting S For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
|---|--|
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () warfarin (COUMADIN) tablet | oral, daily at 1700 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| [] Mechanical Prophylaxis (Single Response) (Sele Required) | ection |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| () Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |
| () HIGH Risk of DVT - Surgical (Hip/Knee) (Selection Required) | |

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

| [1] High Diels (Calaaties Descriped) | |
|---|--|
| [] High Risk (Selection Required) | |
| [] High risk of VTE | Routine, Once, PACU & Post-op |
| [] High Risk Pharmacological Prophylaxis - Hip of (Arthroplasty) Surgical Patient (Single Respon (Selection Required) | |
| () Contraindications exist for pharmacologic | Routine, Once |
| prophylaxis | No pharmacologic VTE prophylaxis due to the following contraindication(s): |
| () apixaban (ELIQUIS) tablet | 2.5 mg, oral, every 12 hours, Starting S+1 Indications: |
| () aspirin chewable tablet | 162 mg, oral, daily, Starting S+1 |
| () aspirin (ECOTRIN) enteric coated tablet | 162 mg, oral, daily, Starting S+1 |
| () enoxaparin (LOVENOX) injection (Single Res (Selection Required) | sponse) |
| () enoxaparin (LOVENOX) syringe | 40 mg, subcutaneous, daily at 0600, Starting S+1 |
| () enoxaparin (LOVENOX) syringe | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 |
| () enoxaparin (LOVENOX) syringe - For | 30 mg, subcutaneous, daily at 0600, Starting S+1 |
| Patients with CrCL LESS than 30 mL/min | For Patients with CrCL LESS than 30 mL/min. |

| () enoxaparin (LOVENOX) syringe - For | |
|--|---|
| Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min. |
| () enoxaparin (LOVENOX) syringe - For Patients weight between 140 kg or GREATER and CrCl GREATER than 30 mL/min | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1 For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min |
| () fondaparinux (ARIXTRA) injection | 2.5 mg, subcutaneous, daily, Starting S+1 If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| () heparin (porcine) injection | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM |
| () heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs. |
| () rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission | 10 mg, oral, daily at 0600 (TIME CRITICAL), Starting S+1 To be Given on Post Op Day 1. Indications: |
| () warfarin (COUMADIN) tablet | oral, daily at 1700, Starting S+1 Indication: |
| () Pharmacy consult to manage warfarin (COUMADIN) | STAT, Until discontinued, Starting S Indication: |
| [] Mechanical Prophylaxis (Single Response) (Se Required) | |
| () Contraindications exist for mechanical prophylaxis | Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op |
| () Place/Maintain sequential compression device continuous | Routine, Continuous, PACU & Post-op |
| Rh Negative Mother | |
| Nursing | |
| [X] Rhogam Workup: If Mother is Rh Negative, comp Rhogam workup and administer Rh immune glob mcg (or dose determined by lab antibody results) within 72 hours of delivery. | ulin 50 |
| Labs | |
| | |
| [X] Fetal Screen | Conditional Frequency, Starting S For 1 Occurrences Conditional- One activation- If Rh Negative Mom and Rh Positive infant, Post-op |
| | Conditional- One activation- If Rh Negative Mom and Rh |
| [X] Fetal Screen | Conditional- One activation- If Rh Negative Mom and Rh Positive infant, Post-op |
| [X] Fetal Screen | Conditional- One activation- If Rh Negative Mom and Rh Positive infant, Post-op Once, Post-op |
| [X] Fetal Screen [] Rhogam Type and Screen Medication [] rho(D) immune globulin (HYPERRHO/RHOGAM) | Conditional- One activation- If Rh Negative Mom and Rh Positive infant, Post-op Once, Post-op 300 mcg, intramuscular, PRN, Rhogam Workup: If Mother is Rh Negative, complete Rhogam workup and administer Rh immune globulin 50 mcg (or dose determined by lab antibody |
| [X] Fetal Screen [] Rhogam Type and Screen Medication [] rho(D) immune globulin (HYPERRHO/RHOGAM) injection | Conditional- One activation- If Rh Negative Mom and Rh Positive infant, Post-op Once, Post-op 300 mcg, intramuscular, PRN, Rhogam Workup: If Mother is Rh Negative, complete Rhogam workup and administer Rh immune globulin 50 mcg (or dose determined by lab antibody |
| [X] Fetal Screen [] Rhogam Type and Screen Medication [] rho(D) immune globulin (HYPERRHO/RHOGAM) injection Labs Tomorrow Hematology [] CBC with differential | Conditional- One activation- If Rh Negative Mom and Rh Positive infant, Post-op Once, Post-op 300 mcg, intramuscular, PRN, Rhogam Workup: If Mother is Rh Negative, complete Rhogam workup and administer Rh immune globulin 50 mcg (or dose determined by lab antibody results) IM within 72 hours of delivery., For 1 Doses, Post-op AM draw, Starting S+1 For 1 Occurrences, Post-op |
| [X] Fetal Screen [] Rhogam Type and Screen Medication [] rho(D) immune globulin (HYPERRHO/RHOGAM) injection Labs Tomorrow Hematology | Conditional- One activation- If Rh Negative Mom and Rh Positive infant, Post-op Once, Post-op 300 mcg, intramuscular, PRN, Rhogam Workup: If Mother is Rh Negative, complete Rhogam workup and administer Rh immune globulin 50 mcg (or dose determined by lab antibody results) IM within 72 hours of delivery., For 1 Doses, Post-op |

| [] Basic metabolic panel | Once, Post-op |
|--|---------------------|
| Consults | |
| For Physician Consult orders use sidebar | |
| Ancillary Consults | |
| [] Consult to Social Work | Reason for Consult: |
| | Post-op |
| [] Consult to Nutrition Services | Reason For Consult? |
| | Purpose/Topic: |
| | Post-op |
| [] Consult to Respiratory Therapy | Reason for Consult? |
| | Post-op |
| | · |
| | |